• GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of COVID-19 antibody.

• The agreement covers sotrovimab, an investigational single dose monoclonal antibody for treating adults and adolescents (aged 12 years and over and weighing at least 40 kg) with COVID-19 who do not require oxygen supplementation and are at risk of progressing to severe COVID-19.

• This action follows the positive scientific opinion issued by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).

• Sotrovimab is included in the European Commission's portfolio of promising candidate therapies as part of its COVID-19 Therapeutics Strategy.

• In addition, the documentation to support the forthcoming marketing authorization for sotrovimab is under rolling regulatory review with the EMA.

• In June, full results from the Phase 3 COMET-ICE trial showed a 79% reduction in hospitalizations for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial.

• GSK and Vir plan to submit a marketing application to the FDA in 2H of 2021.

• In May, sotrovimab received an emergency use nod from the FDA for treating mild-to-moderate COVID-19.

• Price Action: VIR shares closed at $36.44 on Tuesday, while GSK stock is up 0.58% at $39.75 during the premarket session on the last check Wednesday.

See more from Benzinga

• Click here for options trades from Benzinga

• EMA Starts Rolling Review Of Glaxo - Sanofi COVID-19 Vaccine

• GlaxoSmithKline's Anemia Candidate Shows Promise In Late-Stage Studies

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.